Can FDA Ambiguity Improve Drug Labeling?
Executive Summary
Drug sponsors would have to include a more thorough discussion of their product's pros and cons in labeling if FDA addresses concerns raised by Dartmouth Medical School researchers that prescribers and patients are not told enough about the debate that precedes drug approval.